# Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease

> **NCT02574286** · PHASE4 · COMPLETED · sponsor: **Shire** · enrollment: 21 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** Velaglucerase alfa
- **DIETARY_SUPPLEMENT:** Vitamin D

## Key facts

- **NCT ID:** NCT02574286
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-29
- **Primary completion:** 2020-11-12
- **Final completion:** 2020-11-30
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02574286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02574286, "Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02574286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*